CN109982701A - SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途 - Google Patents

SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途 Download PDF

Info

Publication number
CN109982701A
CN109982701A CN201880004458.0A CN201880004458A CN109982701A CN 109982701 A CN109982701 A CN 109982701A CN 201880004458 A CN201880004458 A CN 201880004458A CN 109982701 A CN109982701 A CN 109982701A
Authority
CN
China
Prior art keywords
alkyl
heteroaryl
aryl
naphthenic base
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
CN201880004458.0A
Other languages
English (en)
Other versions
CN109982701B (zh
Inventor
黄晓星
曹国庆
杨昌永
张连山
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Original Assignee
Jiangsu Hengrui Medicine Co Ltd
Shanghai Hengrui Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jiangsu Hengrui Medicine Co Ltd, Shanghai Hengrui Pharmaceutical Co Ltd filed Critical Jiangsu Hengrui Medicine Co Ltd
Publication of CN109982701A publication Critical patent/CN109982701A/zh
Application granted granted Critical
Publication of CN109982701B publication Critical patent/CN109982701B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

提供了一种SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途。具体而言，提供了一种选择性雌激素受体下调剂(SERD)与选自细胞周期蛋白依赖性激酶4/6抑制剂(CDK4/6)、磷脂酰肌醇3‑激酶(PI3K)/雷帕霉素靶蛋白(mTOR)通路抑制剂的一种或多种联合在制备治疗乳腺肿瘤的药物中的用途。

Description

PCT国内申请，说明书已公开。

Claims (21)

  1. PCT国内申请，权利要求书已公开。
CN201880004458.0A 2017-06-21 2018-06-20 SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途 Active CN109982701B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN201710472481X 2017-06-21
CN201710472481 2017-06-21
PCT/CN2018/091930 WO2018233620A1 (zh) 2017-06-21 2018-06-20 SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途

Publications (2)

Publication Number Publication Date
CN109982701A true CN109982701A (zh) 2019-07-05
CN109982701B CN109982701B (zh) 2022-04-12

Family

ID=64737473

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201880004458.0A Active CN109982701B (zh) 2017-06-21 2018-06-20 SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途

Country Status (3)

Country Link
CN (1) CN109982701B (zh)
TW (1) TW201904574A (zh)
WO (1) WO2018233620A1 (zh)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111658774A (zh) * 2020-06-19 2020-09-15 陈长宏 一种促肿瘤细胞增殖周期进展药物联合化疗应用于恶性肿瘤的治疗方法
CN114748480A (zh) * 2021-01-08 2022-07-15 轩竹生物科技股份有限公司 一种预防和/或治疗癌症的药物组合物
CN115936506A (zh) * 2022-12-07 2023-04-07 国网江苏省电力有限公司电力科学研究院 一种基于fce法的风储联合调频系统评估方法、设备及介质
WO2024088392A1 (zh) * 2022-10-28 2024-05-02 南京再明医药有限公司 用于治疗肿瘤的药物组合、药物组合物及其用途

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019136451A1 (en) 2018-01-08 2019-07-11 G1 Therapeutics, Inc. G1t38 superior dosage regimes
WO2021030248A1 (en) 2019-08-12 2021-02-18 Genentech, Inc. Treatment of breast cancer using combination therapies comprising an atp competitive akt inhibitor, a cdk4/6 inhibitor, and fulvestrant
CN115348963B (zh) * 2021-03-08 2024-04-19 暨南大学 吡啶并嘧啶类化合物及其应用

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
WO2014183520A1 (zh) * 2013-05-17 2014-11-20 上海恒瑞医药有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1113007A1 (en) * 1999-12-24 2001-07-04 Pfizer Inc. Tetrahydroisoquinoline compounds as estrogen agonists/antagonists
WO2014183520A1 (zh) * 2013-05-17 2014-11-20 上海恒瑞医药有限公司 吡啶并嘧啶类衍生物、其制备方法及其在医药上的应用

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111658774A (zh) * 2020-06-19 2020-09-15 陈长宏 一种促肿瘤细胞增殖周期进展药物联合化疗应用于恶性肿瘤的治疗方法
CN114748480A (zh) * 2021-01-08 2022-07-15 轩竹生物科技股份有限公司 一种预防和/或治疗癌症的药物组合物
CN114748480B (zh) * 2021-01-08 2023-10-20 轩竹生物科技股份有限公司 一种预防和/或治疗癌症的药物组合物
WO2024088392A1 (zh) * 2022-10-28 2024-05-02 南京再明医药有限公司 用于治疗肿瘤的药物组合、药物组合物及其用途
CN115936506A (zh) * 2022-12-07 2023-04-07 国网江苏省电力有限公司电力科学研究院 一种基于fce法的风储联合调频系统评估方法、设备及介质
CN115936506B (zh) * 2022-12-07 2023-11-24 国网江苏省电力有限公司电力科学研究院 一种基于fce法的风储联合调频系统评估方法、设备及介质

Also Published As

Publication number Publication date
WO2018233620A1 (zh) 2018-12-27
CN109982701B (zh) 2022-04-12
TW201904574A (zh) 2019-02-01

Similar Documents

Publication Publication Date Title
CN109982701A (zh) SERD与CDK4/6抑制剂、PI3K/mTOR通路抑制剂的用途
CN109562106B (zh) Cxcr4抑制剂及其用途
Heretsch et al. Cyclopamine and hedgehog signaling: chemistry, biology, medical perspectives
CN104478875B (zh) 聚(adp‑核糖)聚合酶(parp)的二氢吡啶并酞嗪酮抑制剂
CA2844699C (en) Combinations of akt inhibitor compounds and abiraterone, and methods of use
CN107406438A (zh) 溴结构域的抑制剂
JP7348665B2 (ja) 選択的エストロゲン受容体分解剤としての置換ベンゾチオフェン類似体
JP2022500384A (ja) 組み合わせ療法
CN109906224A (zh) 三唑吡啶化合物及其应用
CN108699024A (zh) 苯并噻吩基选择性雌激素受体下调剂化合物
CN110461853A (zh) 苯并噻吩雌激素受体调节剂
CN109937041A (zh) 一种ezh2抑制剂与btk抑制剂联合在制备治疗肿瘤的药物中的用途
CN108349952A (zh) 四氢萘雌激素受体调节剂及其用途
AU2018234985B2 (en) Deuterated imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
JP2022500381A (ja) 組み合わせ療法
JP2022500388A (ja) 組み合わせ療法
CN109789144A (zh) 蛋白激酶调节剂
JP2022539840A (ja) Ｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ１（ｍｎｋ１）及びｍａｐキナーゼ相互作用セリン／スレオニン－プロテインキナーゼ２（ｍｎｋ２）の阻害剤、癌治療及び治療的組合せ
AU2016329513B2 (en) 2-Aminoquinazoline derivatives as p70S6 kinase inhibitors
CN108586443B (zh) 一种防治支气管肺癌的药物及其制备方法
CN106565685A (zh) 微管蛋白抑制剂
CN105924444A (zh) Jak抑制剂的晶型及其制备方法
CN110730782B (zh) 光动力治疗化合物和光动力治疗方法
CN116535389B (zh) 6-吡啶-3-喹喔啉脲类衍生物及其用途
EP4079306A1 (en) Therapeutic agent containing fused pyrimidine compound as active ingredient

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant